Explore related pages
Related company profiles:
News
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers - Pharmaceutical Executive
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers Pharmaceutical Executive
Pfizer buys into PD-1/VEGF competition with 3SBio deal - BioPharma Dive
Pfizer buys into PD-1/VEGF competition with 3SBio deal BioPharma Dive
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio - Oncodaily
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio Oncodaily
Pfizer and 3SBio conclude licensing deal for SSGJ-707 - Pharmaceutical Technology
Pfizer and 3SBio conclude licensing deal for SSGJ-707 Pharmaceutical Technology
ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Pfizer Enters into Exclusive Licensing Agreement with 3SBio - Business Wire
Pfizer Enters into Exclusive Licensing Agreement with 3SBio Business Wire
Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio - Fierce Pharma
Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio Fierce Pharma
Pfizer Licenses 3SBio Cancer Drug For Record $1.2 Billion - Bloomberg
Pfizer Licenses 3SBio Cancer Drug For Record $1.2 Billion Bloomberg
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China Investopedia
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race - BioWorld MedTech
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race BioWorld MedTech
Han Kun advises 3SBio in landmark Pfizer licensing deal - Law.asia
Han Kun advises 3SBio in landmark Pfizer licensing deal Law.asia
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake - Reuters
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake Reuters
Pfizer enters into exclusive licensing agreement worth $4.8 B with China's 3SBio - BioSpectrum Asia
Pfizer enters into exclusive licensing agreement worth $4.8 B with China's 3SBio BioSpectrum Asia
3SBio hits the big time with $6 billion cancer drug deal - thebambooworks.com
3SBio hits the big time with $6 billion cancer drug deal thebambooworks.com
Pfizer Completes Licensing Agreement with 3SBio - Business Wire
Pfizer Completes Licensing Agreement with 3SBio Business Wire
Pfizer completes licensing agreement with 3SBio - Express Pharma
Pfizer completes licensing agreement with 3SBio Express Pharma
Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody - BioWorld MedTech
Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody BioWorld MedTech
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% - PR Newswire
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% PR Newswire
Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc. - Yahoo Finance
Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc. Yahoo Finance
Pfizer signs global licensing deal with 3SBio for bispecific antibody - Pharmaceutical Technology
Pfizer signs global licensing deal with 3SBio for bispecific antibody Pharmaceutical Technology
Arvinas and 3SBio hope to do better | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Arvinas and 3SBio hope to do better | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced - PR Newswire
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced PR Newswire
Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy - MedCity News
Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy MedCity News
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF - BioPharm International
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF BioPharm International
Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn - PMLiVE
Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn PMLiVE
3SBio Partners with Pfizer for Global Licensing of Oncology Antibody - TipRanks
3SBio Partners with Pfizer for Global Licensing of Oncology Antibody TipRanks
Pfizer Thinks Bigger With 3SBio Deal (NYSE:PFE) - Seeking Alpha
Pfizer Thinks Bigger With 3SBio Deal (NYSE:PFE) Seeking Alpha
Chinese biotech firm secures Pfizer deal despite trade tensions - South China Morning Post
Chinese biotech firm secures Pfizer deal despite trade tensions South China Morning Post
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug - The Economic Times
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug The Economic Times
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth - PR Newswire
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth PR Newswire
3Sbio licenses out global rights of PD-1 inhibitor to Syncromune - BioWorld MedTech
3Sbio licenses out global rights of PD-1 inhibitor to Syncromune BioWorld MedTech
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China - GlobeNewswire
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China GlobeNewswire
3SBio and Pfizer Finalize License Agreement and Share Subscription - TipRanks
3SBio and Pfizer Finalize License Agreement and Share Subscription TipRanks
China's 3SBio surges over 37% after $6B Pfizer deal - breakingthenews.net
China's 3SBio surges over 37% after $6B Pfizer deal breakingthenews.net
3SBio enters licensing deal for antibody-drug conjugate ALT-P7 - Drug Target Review
3SBio enters licensing deal for antibody-drug conjugate ALT-P7 Drug Target Review
Pfizer signs licensing deal worth about US$6 billion with China's 3SBio for cancer drug - The Standard (HK)
Pfizer signs licensing deal worth about US$6 billion with China's 3SBio for cancer drug The Standard (HK)
3SBio Q4 11 Earnings Conference Call At 8:00 AM ET - RTTNews
3SBio Q4 11 Earnings Conference Call At 8:00 AM ET RTTNews
AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China - Fierce Pharma
AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China Fierce Pharma
3SBio & Selecta To Develop Non-Immunogenic Gout Drug - Asian Scientist Magazine
3SBio & Selecta To Develop Non-Immunogenic Gout Drug Asian Scientist Magazine
3SBio: Firm hold over biopharma - Forbes India
3SBio: Firm hold over biopharma Forbes India
3SBio appoints Kevin Xiao Weihong as new COO - BioSpectrum Asia
3SBio appoints Kevin Xiao Weihong as new COO BioSpectrum Asia
Top 3Sbio Inc. Employees
-
Hao Zhang
Corporate Development
Shanghai, China, China1gmail.com -
-
Jialu YUAN
n/a
Shanghai, China, China13sbio.com -
Haomin Huang
Vice President, R&D, At 3Sbio Inc.
Cranbury, New Jersey, United States, United States3hotmail.com, oncobiologics.com, oncobiologics.com1 +160961XXXXX
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.